Skip to main content
SpringerLink
Log in
Book cover

Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors pp 351–361Cite as

Radionuclide Imaging of Pancreatic Neuroendocrine Tumours

  • Chapter
  • First Online:

  • 1157 Accesses

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

Pancreatic neuroendocrine neoplasm (pNEN) prevalence is increasing as a consequence of both the improvement of diagnostic procedures and therapeutic options. Although pNEN is characterised by an overall better prognosis as compared to other forms of solid tumours, the patient outcome can vary greatly.

Although conventional imaging procedures (including endoscopic ultrasound, CT and MR) can be employed, imaging of pNEN was completely revolutionised by the introduction of somatostatin receptor imaging (SRI), first by means of scintigraphy followed by PET/CT. In fact, the possibility to non-invasively provide data on somatostatin receptor expression on neuroendocrine tumour (NET) cells has implication not only for diagnosis but also for treatment planning and prognosis. Although SRI plays a central role in the management of pNEN patients, other radiopharmaceuticals (18 F-FDG, 18 F-DOPA and 68Ga-exedin4) have been used and may provide additional data.

The present chapter focuses on the various radiopharmaceuticals that have been employed to study pNEN with particular emphasis to those that provide a clear advantage for clinical management.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Koopmans KP, Neels ON, Kema IP, Elsinga PH, Links TP, de Vries EGE, et al. Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol. 2009;71(3):199–213.

    Article  PubMed  Google Scholar 

  2. Leung D, Schwartz L. Imaging of neuroendocrine tumors. Semin Oncol. 2013;40(1):109–19.

    Article  PubMed  Google Scholar 

  3. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61(1):6–32.

    Article  CAS  PubMed  Google Scholar 

  4. Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000;95(9):2271–7.

    Article  CAS  PubMed  Google Scholar 

  5. Pais SA, Al-Haddad M, Mohamadnejad M, Leblanc JK, Sherman S, McHenry L, et al. EUS for pancreatic neuroendocrine tumors: a single-center, 11-year experience. Gastrointest Endosc. 2010;71(7):1185–93.

    Article  PubMed  Google Scholar 

  6. Hijioka S, Hara K, Mizuno N, Imaoka H, Bhatia V, Mekky MA, et al. Diagnostic performance and factors influencing the accuracy of EUS-FNA of pancreatic neuroendocrine neoplasms. J Gastroenterol. 2016;14:923–30.

    Article  Google Scholar 

  7. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20(8):716–31.

    Article  CAS  PubMed  Google Scholar 

  8. Kowalski J, Henze M, Schuhmacher J, Mäcke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol MIB Off Publ Acad Mol Imaging. 2003;5(1):42–8.

    Article  Google Scholar 

  9. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34(10):1617–26.

    Article  CAS  PubMed  Google Scholar 

  10. Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med Off Publ Soc Nucl Med. 2010;51(6):875–82.

    CAS  Google Scholar 

  11. Schreiter NF, Brenner W, Nogami M, Buchert R, Huppertz A, Pape U-F, et al. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39(1):72–82.

    Article  PubMed  Google Scholar 

  12. Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med Off Publ Soc Nucl Med. 2009;50(9):1427–34.

    CAS  Google Scholar 

  13. Ambrosini V, Campana D, Tomassetti P, Fanti S. 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 1:S52–60.

    Article  PubMed  Google Scholar 

  14. Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37(10):2004–10.

    Article  PubMed  Google Scholar 

  15. Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med. 1998;25(10):1396–403.

    Article  CAS  PubMed  Google Scholar 

  16. Etchebehere EC, de Oliveira Santos A, Gumz B, Vicente A, Hoff PG, Corradi G, et al. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. J Nucl Med Off Publ Soc Nucl Med. 2014;55(10):1598–604.

    Google Scholar 

  17. Skoura E, Michopoulou S, Mohmaduvesh M, Panagiotidis E, Al Harbi M, Toumpanakis C, et al. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom. J Nucl Med Off Publ Soc Nucl Med. 2016;57(1):34–40.

    CAS  Google Scholar 

  18. Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010;51(5):669–73.

    Article  PubMed  Google Scholar 

  19. Ilhan H, Fendler WP, Cyran CC, Spitzweg C, Auernhammer CJ, Gildehaus F-J, et al. Impact of (68)Ga-DOTATATE PET/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum. Ann Surg Oncol. 2015;22(1):164–71.

    Article  PubMed  Google Scholar 

  20. Campana D, Ambrosini V, Pezzilli R, Fanti S, Labate AMM, Santini D, et al. Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med Off Publ Soc Nucl Med. 2010;51(3):353–9.

    Google Scholar 

  21. Kaemmerer D, Wirtz RM, Fischer EK, Hommann M, Sänger J, Prasad V, et al. Analysis of somatostatin receptor 2A immunohistochemistry, RT-qPCR, and in vivo PET/CT data in patients with pancreatic neuroendocrine neoplasm. Pancreas. 2015;44(4):648–54.

    CAS  PubMed  Google Scholar 

  22. Boy C, Heusner TA, Poeppel TD, Redmann-Bischofs A, Unger N, Jentzen W, et al. 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging. 2011;38(7):1224–36.

    Article  CAS  PubMed  Google Scholar 

  23. Ambrosini V, Campana D, Polverari G, Peterle C, Diodato S, Ricci C, et al. Prognostic value of 68Ga-DOTANOC PET/CT SUVmax in patients with neuroendocrine tumors of the pancreas. J Nucl Med Off Publ Soc Nucl Med. 2015;56(12):1843–8.

    CAS  Google Scholar 

  24. Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, et al. SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors. Mol Imaging Biol MIB Off Publ Acad Mol Imaging. 2015;17(3):313–8.

    Article  CAS  Google Scholar 

  25. Has Simsek D, Kuyumcu S, Turkmen C, Sanlı Y, Aykan F, Unal S, et al. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? J Nucl Med Off Publ Soc Nucl Med. 2014;55(11):1811–7.

    Google Scholar 

  26. Bahri H, Laurence L, Edeline J, Leghzali H, Devillers A, Raoul J-L, et al. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation. J Nucl Med Off Publ Soc Nucl Med. 2014;55(11):1786–90.

    CAS  Google Scholar 

  27. Partelli S, Rinzivillo M, Maurizi A, Panzuto F, Salgarello M, Polenta V, et al. The role of combined Ga-DOTANOC and (18)FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors. Neuroendocrinology. 2014;100(4):293–9.

    Article  CAS  PubMed  Google Scholar 

  28. Garin E, Le Jeune F, Devillers A, Cuggia M, de Lajarte-Thirouard A-S, Bouriel C, et al. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med Off Publ Soc Nucl Med. 2009;50(6):858–64.

    CAS  Google Scholar 

  29. Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, et al. Diagnosis and management of insulinoma. World J Gastroenterol. 2013;19(6):829–37.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Scherübl H, Streller B, Stabenow R, Herbst H, Höpfner M, Schwertner C, et al. Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J Gastroenterol. 2013;19(47):9012–9.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Hirshberg B, Cochran C, Skarulis MC, Libutti SK, Alexander HR, Wood BJ, et al. Malignant insulinoma: spectrum of unusual clinical features. Cancer. 2005;104(2):264–72.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Wild D, Christ E, Caplin ME, Kurzawinski TR, Forrer F, Brändle M, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med Off Publ Soc Nucl Med. 2011;52(7):1073–8.

    Google Scholar 

  33. Eriksson O, Velikyan I, Selvaraju RK, Kandeel F, Johansson L, Antoni G, et al. Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report. J Clin Endocrinol Metab. 2014;99(5):1519–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Antwi K, Fani M, Nicolas G, Rottenburger C, Heye T, Reubi JC, et al. Localization of hidden insulinomas with 68Ga-DOTA-exendin-4 PET/CT: A Pilot Study. J Nucl Med Off Publ Soc Nucl Med. 2015;56(7):1075–8.

    CAS  Google Scholar 

  35. Ambrosini V, Campana D, Nanni C, Marzola MC, Rubello D, Fanti S. 68Ga DOTANOC PET/CT detects primary malignant insulinoma. Clin Nucl Med. 2015;40(2):e132–3.

    Article  PubMed  Google Scholar 

  36. Chondrogiannis S, Grassetto G, Marzola MC, Rampin L, Massaro A, Bellan E, et al. 18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours. Nucl Med Commun. 2012;33(2):179–84.

    Article  CAS  PubMed  Google Scholar 

  37. Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35(8):1431–8.

    Article  CAS  PubMed  Google Scholar 

  38. Haug A, Auernhammer CJ, Wängler B, Tiling R, Schmidt G, Göke B, et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2009;36(5):765–70.

    Article  CAS  PubMed  Google Scholar 

  39. Imperiale A, Sebag F, Vix M, Castinetti F, Kessler L, Moreau F, et al. 18F-FDOPA PET/CT imaging of insulinoma revisited. Eur J Nucl Med Mol Imaging. 2015;42(3):409–18.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine, DIMES, Alma Mater Studiorum University of Bologna, S. Orsola-Malpighi Hospital, Via Massarenti 9, 40138, Bologna, Italy

    Valentina Ambrosini MD, PhD & Stefano Fanti MD

Authors
  1. Valentina Ambrosini MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefano Fanti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valentina Ambrosini MD, PhD .

Editor information

Editors and Affiliations

  1. Section on Medical Neuroendocrinology, Eunice Kennedy Shriver NICHD, NIH, Bethesda, Maryland, USA

    Karel Pacak

  2. Department of Nuclear Medicine, Aix-Marseille University, Marseille, France

    David Taïeb

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Ambrosini, V., Fanti, S. (2017). Radionuclide Imaging of Pancreatic Neuroendocrine Tumours. In: Pacak, K., Taïeb, D. (eds) Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors. Contemporary Endocrinology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-46038-3_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-46038-3_16

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-46036-9

  • Online ISBN: 978-3-319-46038-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation